Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.La Jolla gets fast track status for Riquent as funds run down
In October 2004, the FDA informed La Jolla that Riquent (abetimus sodium) was “approvable” pending the successful completion of a clinical benefit trial. A clinical benefit trial designed
In October 2004, the FDA informed La Jolla that Riquent (abetimus sodium) was “approvable” pending the successful completion of a clinical benefit trial. A clinical benefit trial designed
The VR1 receptor is an ion channel protein that mediates and influences cell signaling, including the nerve cell signaling that generates some types of pain. Inhibitors of VR1
The objectives of the phase I clinical protocol are to evaluate safety, pharmacokinetics and viral load in patients chronically infected with Hepatitis C virus (HCV) who have failed
A similar phase I clinical trial for Neumune is currently ongoing in the Netherlands. Acute Radiation Syndrome (ARS) is a potentially lethal condition caused by high-dose radiation exposure
The use of cholesterol-lowering drugs known as statins to reduce the risk of heart disease has exploded in recent years, but the new Stanford study shows that doctors
Under the terms of the license agreement Pfizer will have the right to use the ACE System internally to engineer cell lines for product research, development and manufacturing.
The company began submitting data for the application in April 2005. The filings are based on clinical data supporting that both indiplon capsules and tablets show significant improvement
The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion to extend the use of Arixtra (fondaparinux sodium) to patients judged
Results indicate that patients with inadequately controlled severe persistent asthma, who are at high risk of life-threatening attacks, substantially benefit from treatment with omalizumab, marketed as Xolair. These
The Centers for Disease Control and Prevention (CDC) is calling for routine meningococcal disease vaccination to be given during preadolescent doctors’ visits between the ages of 11 to